Stock MOLN MOLECULAR PARTNERS AG
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Molecular Partners AG

Equities

MOLN

CH0256379097

Market Closed - Swiss Exchange
Other stock markets
 11:31:30 2024-04-26 am EDT 		5-day change 1st Jan Change
3.36 CHF +5.00% Intraday chart for Molecular Partners AG -0.30% -2.33%
Mar. 15 Transcript : Molecular Partners AG, 2023 Earnings Call, Mar 15, 2024
Mar. 15 Molecular Partners Swings to Loss in FY23; Revenue Down MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Molecular Partners : Annual General Meeting Minutes
PU
Life Science Cares Launches in Switzerland
GL
Molecular Partners : statement regarding Passive Foreign Investment Company status
PU
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GL
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
AQ
Court Dismisses Class Action Against Biopharmaceutical Company For Failing To Disclose Progress Of Competitor; Second Circuit Affirms Dismissal Of Putative Class Action Against Allergan; Eleventh Circuit Affirms That "Toxic" Lender Qualified As A "Dealer" Under The Exchange Act Due To High-Volume Trading; Delaware Court Of Chancery Invalidates Governance Rights In Stockholder Agreement
AQ
Molecular Partners Publishes Invitation to Annual General Meeting 2024
GL
Molecular Partners Publishes Invitation to Annual General Meeting 2024
AQ
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GL
Molecular Partners Announces Dismissal of Class Action Lawsuit
GL
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
GL
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
AQ
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
AQ
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
AQ
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
AQ
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
AQ
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
GL
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
AQ
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
AQ
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MOLN Stock
  4. News Molecular Partners AG
  5. Press Releases